The discovery of phenylbenzamide derivatives as Grb7-based antitumor agents

Nigus Dessalew Ambaye, Menachem Joseph Gunzburg, Reece Chih Chian Lim, John Timothy Price, Matthew Charles James Wilce, Jacqueline Anne Wilce

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Grb7 is a non-catalytic protein, the overexpression of which has been associated with the proliferative and migratory potentials of cancer cells. Virtual screening strategies involving a shape-based similarity search, molecular docking, and 2D-similarity searches complemented by experimental binding studies (Thermofluor and isothermal titration calorimetry) resulted in the identification of nine novel phenylbenzamide-based antagonists of the Grb7 SH2 domain. Moderate binding affinities were observed, ranging from K(d)=32.3 muM for lead phenylbenzamide NSC 104999 (1) to K(d)=1.1 muM for a structurally related compound, NSC 57148 (2). Deconvolution of the affinity data into its components revealed differences in lead binding, from being entropy based (lead 1) to enthalpically driven (NSC 100874 (3), NSC 55158 (4), and compound 2). Finally, the lead compound 1 was found to decrease the growth of MDA-MB-468 breast cancer cells, with an IC(50) value of 39.9 muM. It is expected that these structures will serve as novel leads in the development of Grb7-based anticancer therapeutics.
Original languageEnglish
Pages (from-to)280 - 288
Number of pages9
JournalChemMedChem
Volume8
Issue number2
DOIs
Publication statusPublished - 2013

Cite this

Ambaye, Nigus Dessalew ; Gunzburg, Menachem Joseph ; Lim, Reece Chih Chian ; Price, John Timothy ; Wilce, Matthew Charles James ; Wilce, Jacqueline Anne. / The discovery of phenylbenzamide derivatives as Grb7-based antitumor agents. In: ChemMedChem. 2013 ; Vol. 8, No. 2. pp. 280 - 288.
@article{eff69bdc9cf8459d9bf92421ae4fb3f7,
title = "The discovery of phenylbenzamide derivatives as Grb7-based antitumor agents",
abstract = "Grb7 is a non-catalytic protein, the overexpression of which has been associated with the proliferative and migratory potentials of cancer cells. Virtual screening strategies involving a shape-based similarity search, molecular docking, and 2D-similarity searches complemented by experimental binding studies (Thermofluor and isothermal titration calorimetry) resulted in the identification of nine novel phenylbenzamide-based antagonists of the Grb7 SH2 domain. Moderate binding affinities were observed, ranging from K(d)=32.3 muM for lead phenylbenzamide NSC 104999 (1) to K(d)=1.1 muM for a structurally related compound, NSC 57148 (2). Deconvolution of the affinity data into its components revealed differences in lead binding, from being entropy based (lead 1) to enthalpically driven (NSC 100874 (3), NSC 55158 (4), and compound 2). Finally, the lead compound 1 was found to decrease the growth of MDA-MB-468 breast cancer cells, with an IC(50) value of 39.9 muM. It is expected that these structures will serve as novel leads in the development of Grb7-based anticancer therapeutics.",
author = "Ambaye, {Nigus Dessalew} and Gunzburg, {Menachem Joseph} and Lim, {Reece Chih Chian} and Price, {John Timothy} and Wilce, {Matthew Charles James} and Wilce, {Jacqueline Anne}",
year = "2013",
doi = "10.1002/cmdc.201200400",
language = "English",
volume = "8",
pages = "280 -- 288",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "Wiley-VCH Verlag GmbH & Co. KGaA",
number = "2",

}

The discovery of phenylbenzamide derivatives as Grb7-based antitumor agents. / Ambaye, Nigus Dessalew; Gunzburg, Menachem Joseph; Lim, Reece Chih Chian; Price, John Timothy; Wilce, Matthew Charles James; Wilce, Jacqueline Anne.

In: ChemMedChem, Vol. 8, No. 2, 2013, p. 280 - 288.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The discovery of phenylbenzamide derivatives as Grb7-based antitumor agents

AU - Ambaye, Nigus Dessalew

AU - Gunzburg, Menachem Joseph

AU - Lim, Reece Chih Chian

AU - Price, John Timothy

AU - Wilce, Matthew Charles James

AU - Wilce, Jacqueline Anne

PY - 2013

Y1 - 2013

N2 - Grb7 is a non-catalytic protein, the overexpression of which has been associated with the proliferative and migratory potentials of cancer cells. Virtual screening strategies involving a shape-based similarity search, molecular docking, and 2D-similarity searches complemented by experimental binding studies (Thermofluor and isothermal titration calorimetry) resulted in the identification of nine novel phenylbenzamide-based antagonists of the Grb7 SH2 domain. Moderate binding affinities were observed, ranging from K(d)=32.3 muM for lead phenylbenzamide NSC 104999 (1) to K(d)=1.1 muM for a structurally related compound, NSC 57148 (2). Deconvolution of the affinity data into its components revealed differences in lead binding, from being entropy based (lead 1) to enthalpically driven (NSC 100874 (3), NSC 55158 (4), and compound 2). Finally, the lead compound 1 was found to decrease the growth of MDA-MB-468 breast cancer cells, with an IC(50) value of 39.9 muM. It is expected that these structures will serve as novel leads in the development of Grb7-based anticancer therapeutics.

AB - Grb7 is a non-catalytic protein, the overexpression of which has been associated with the proliferative and migratory potentials of cancer cells. Virtual screening strategies involving a shape-based similarity search, molecular docking, and 2D-similarity searches complemented by experimental binding studies (Thermofluor and isothermal titration calorimetry) resulted in the identification of nine novel phenylbenzamide-based antagonists of the Grb7 SH2 domain. Moderate binding affinities were observed, ranging from K(d)=32.3 muM for lead phenylbenzamide NSC 104999 (1) to K(d)=1.1 muM for a structurally related compound, NSC 57148 (2). Deconvolution of the affinity data into its components revealed differences in lead binding, from being entropy based (lead 1) to enthalpically driven (NSC 100874 (3), NSC 55158 (4), and compound 2). Finally, the lead compound 1 was found to decrease the growth of MDA-MB-468 breast cancer cells, with an IC(50) value of 39.9 muM. It is expected that these structures will serve as novel leads in the development of Grb7-based anticancer therapeutics.

UR - http://onlinelibrary.wiley.com/doi/10.1002/cmdc.201200400/pdf

U2 - 10.1002/cmdc.201200400

DO - 10.1002/cmdc.201200400

M3 - Article

VL - 8

SP - 280

EP - 288

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 2

ER -